LOUISVILLE, Ky. — Cognision, a provider of advanced neurobiomarker technology, announced a partnership with Kynexis to deploy the COGNISION System in Kynexis’ Phase 2 clinical trial evaluating KYN-5356 in individuals with schizophrenia.
KYN-5356 is designed to inhibit KAT-II, an enzyme in the kynurenine pathway associated with cognitive impairment in schizophrenia, a debilitating symptom with no approved treatments. The ongoing Phase 2 trial aims to establish proof of clinical concept for KYN-5356 by assessing its ability to improve cognitive performance.
Kynexis selected the COGNISION platform to capture precise, objective measurements of drug-related changes in brain activity. EEG and ERP testing conducted after dosing with either KYN-5356 or a placebo provides data linking therapeutic effects to biomarkers tied to the drug’s mechanism of action and underlying disease biology.
“We are pleased to collaborate with Kynexis on this important clinical study,” said Marco Cecchi, CSO of Cognision. “Our EEG and ERP platform enables objective measurement of neural activity and cognitive processing in real time. By assessing the effects of KYN-5356 on brain function in individuals with schizophrenia, we aim to provide early neurophysiological markers of drug response that may inform the development of more targeted and effective therapies for this population.”
“By integrating Cognision’s EEG/ERP platform into our KYN-5356 trial, we’re able to enrich our primary cognitive assessments with complementary, objective data on brain function,” said Dr. Jens Wendland, Chief Medical Officer at Kynexis. “This collaboration allows us to better understand the relationship between cognitive outcomes and underlying neurophysiology, strengthening our approach to developing KYN-5356 in CIAS.”
